The therapeutic relevance of Локоид Липокрем is associated with symptomatic relief across key dermatological domains where supportive topical treatment is required. Its use is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is commonly used when symptoms that become more disruptive during flare-ups intensify, and it is designed to provide symptomatic relief that helps patients cope more steadily.

This medication is generally applicable within conditions characterized by periods of heightened symptoms, helping to ease clusters of symptoms like redness, swelling, and severe itching. It is frequently used for managing conditions such as eczema, various forms of dermatitis, and localized patches of psoriasis.

The application is relevant for easing challenging symptoms, contributing to improved comfort during periods of heightened symptoms.

This preparation provides support that helps ease the overall symptom burden in adults and appropriate pediatric patients with mild to moderate atopic dermatitis. It is applied in clinical settings that involve acute or unstable symptom patterns, supporting general well-being during symptomatic phases.

---

Quick Fact: Relief for Key Symptoms
Main Symptom Axis	Inflammatory and Pruritic Manifestations
Common Use Context	Episodic flares of chronic dermatoses
Patient Benefit	Contributes to improved day-to-day comfort
Specific Focus	Easing severe itching and skin redness

---

Regulatory References

1. NIH DailyMed Label for Hydrocortisone Butyrate

The official eligibility for Локоид Липокрем (Hydrocortisone butyrate 0.1%) is strictly defined by regulatory documentation concerning patient age, medical status, and local conditions.

Populations Allowed and Age-Related Rules

Use is established for adults and pediatric patients 3 months of age and older. Safety and efficacy have not been established for infants under 3 months of age, constituting a use-not-established group. No special dosage regimen is necessary for older adults.

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity to the active ingredient or excipients. Use is also formally prohibited in the presence of specific local conditions, including rosacea, acne vulgaris, peri-oral dermatitis, and untreated local bacterial, viral, fungal, or syphilitic infections in the area to be treated.

Conditional Use and Restrictions

For infants 3 months and older, therapy is typically restricted to a maximum of seven consecutive days. Use in pregnancy (Category C) is conditional, permitted only if the potential benefit justifies the potential risk to the fetus. Breastfeeding women must avoid applying the cream directly to the breast. Pediatric patients and those with liver failure are identified as populations with increased susceptibility to systemic effects.

Interactions with other medicines and products

The interaction profile of Локоид Липокрем (Hydrocortisone butyrate 0.1% Lipocream) is officially documented by regulatory agencies as having a low risk for classical systemic drug-drug interactions, which is characteristic of topical corticosteroids.

Interaction Classifications

Classification	Official Regulatory Statement
Pharmacokinetic Interactions	None documented (e.g., no known interactions with CYP enzymes or drug transporters).
Contraindicated Combinations	No formal drug-drug contraindications are listed in the official prescribing information.

---

Documented Exposure-Modifying Interaction

The sole documented interaction-related restriction pertains to a pharmacodynamic class effect involving the use of other corticosteroid-containing products. Co-administration with other topical or systemic corticosteroids may result in additive systemic glucocorticoid exposure.

This additive exposure is officially documented as increasing the potential for systemic adverse effects, particularly Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Regulatory labeling mandates that the cumulative systemic effect of all concurrent corticosteroid products must be considered.

No specific interaction warnings are documented for co-administration with food, alcohol, or herbal products. The risk of systemic effects from additive exposure is noted to be greater in pediatric patients due to their higher skin surface area to body mass ratio.

Molecular Control of Inflammatory Gene Expression

Локоид Липокрем's active ingredient, Hydrocortisone butyrate, acts as an agonist at the Glucocorticoid Receptor ( GR), which is widely expressed in cutaneous cells. This interaction initiates a genomic mechanism where the drug-receptor complex translocates into the cell nucleus to modulate gene transcription.

This modulation involves two primary, complementary actions. Trans-repression suppresses pro-inflammatory transcription factors like NF-kappa B, reducing the production of inflammatory cytokines and chemokines. Simultaneously, trans-activation increases the synthesis of the anti-inflammatory protein Lipocortin-1, which indirectly blocks the PLA2 enzyme, thereby halting the generation of Prostaglandins and Leukotrienes.

Downstream Physiological Stabilization

This broad suppression of inflammatory mediators leads to specific physiological changes at the tissue level. The mechanism results in the local blood vessels to constrict (vasoconstriction) and reduces their permeability, which stabilizes local fluid dynamics. By reducing the concentration of signaling molecules that stimulate nerve endings, the mechanism also facilitates the attenuation of neural signaling in the affected tissue.

The application of Локоид Липокрем (Hydrocortisone butyrate 0.1% cream) focuses on the technique, dose, and frequency of use.

---

Administration Scope

Feature	Guideline
Route of administration	Cutaneous (Topical) use only.
Dosing schedule	Apply a thin layer to the affected skin area and rub in gently.
Timing in relation to meals (if applicable)	Not applicable.
Preparation requirements (if applicable)	None; the preparation is ready for external use only.
Age-group administration rules	Adults: The regimen is typically two or three times daily. Pediatric patients (3 months and older): Application is generally two times daily, and the treatment period should be limited to the least amount compatible with an effective regimen.
Missed-dose rules	If a dose is missed, it should be applied as soon as possible, or the missed dose should be skipped if the next dose is near, returning to the regular schedule.
Special procedural conditions	The cream is not for oral, ophthalmic, or intravaginal use. Therapy should be discontinued when control is achieved. If no improvement is observed within two weeks, a diagnostic reassessment may be necessary.

---

Instruction Classifications (High-Level)

Classification	Principle
Administration method type	Topical.
Frequency pattern	Daily (typically two or three times daily).
Documentation Type	Prescribing Information.
Use-context constraints	Avoid use under occlusive dressings (e.g., bandages, plastic pants) unless directed. Avoid application on the face, underarms, or groin unless specifically instructed.

---

Resulting Procedural Structure

Step sequence:

• Apply a thin layer of the cream to the affected skin area.
• Gently rub the cream into the affected area.
• Repeat the application as specified by the dosing regimen (two or three times daily).
• Discontinue use once control is achieved; the total duration is generally not established beyond four weeks.

Connection to the overall use protocol: Локоид Липокрем is for topical administration as a thin layer applied directly to the skin, with a defined frequency of use. The protocol involves a short-term duration of use, generally not exceeding four weeks, and requires avoiding occlusive techniques or highly absorptive skin areas to manage the standard parameters of administration. These procedural steps represent the core rules for its proper administration.

Evidence for Use in Atopic Dermatitis and Eczema

Research exploring Hydrocortisone butyrate 0.1% Lipocream has focused on studies evaluating its use for inflammatory skin conditions, primarily atopic dermatitis and general corticosteroid-responsive eczema. The core evidence consists of short-term, randomized controlled trials (RCTs) comparing the Lipocream to other active agents or non-active vehicles. Researchers monitored changes in objective scales like the Investigator Global Assessment (IGA) and the Eczema Area and Severity Index (EASI). Studies included both adult and pediatric patients (children 3 months of age and older) to monitor changes in symptoms such as pruritus and erythema.

---

Evidence for Use in Localized Psoriasis and Chronic Dermatitis

Research has also explored the use of Hydrocortisone butyrate 0.1% for other skin conditions, including localized psoriasis and various forms of chronic dermatitis. This evidence base relies on short-term randomized controlled trials, sometimes using left-right comparison designs where study agents are applied to different areas on the same patient. Studies examined outcomes linked to inflammatory or irritative states by specifically measuring changes in lesion characteristics, such as induration and scaling. In some cases, findings were mixed when research evaluated the product against certain other topical steroids.

---

Long-Term Studies and Research Limitations

The evidence base consists primarily of studies with short-term follow-up durations, typically lasting only a few weeks. Long-term effects are not fully established because the existing research provides limited insight into changes that occur over many months. The evidence base also contributes to understanding short-term changes in temporary physiological imbalance or acute symptoms in pediatric patients, where dedicated studies evaluated the HPA axis status following application. Certainty remains low regarding the full range of outcomes after use beyond the initial month of therapy.

Key Studies & References

1. Label: HYDROCORTISONE BUTYRATE cream - DailyMed - NIH (U.S. Regulatory Information)

Common questions about Локоид Липокрем (FAQ)

Q: Is this product considered a mild steroid?

The active ingredient in Локоид Липокрем, Hydrocortisone butyrate 0.1%, is classified by regulatory documents as a moderately potent topical corticosteroid. This classification is based on the comparative strength of its anti-inflammatory effect.

---

Q: Can Локоид Липокрем be used for rashes that are not eczema?

Official product information states that the medicine is indicated for relieving the inflammatory and itchy symptoms of corticosteroid-responsive dermatoses. This broad category, as described in research, includes conditions beyond just eczema and atopic dermatitis, such as localized psoriasis.

---

Q: Are there any specific parts of the body where Локоид Липокрем should not be used?

Regulatory guidelines indicate that the cream should generally be avoided on sensitive areas like the face, underarms, and groin unless a healthcare professional specifically directs it. Additionally, contact with the eyes should be avoided due to the potential risk of serious ophthalmic issues like glaucoma or cataracts.

---

Q: Can Локоид Липокрем be used during pregnancy, according to official sources?

The use of the product during pregnancy is classified as conditional (Category C) in official documents. This means it may be used only after a healthcare provider has determined that the potential benefit to the mother justifies the potential risk to the fetus.

---

Q: What are the official guidelines regarding the use of Локоид Липокрем while breastfeeding?

Official guidelines suggest avoiding application directly to the breast area to prevent potential ingestion by the infant. As with all medications, the potential for adverse effects in the child is a factor to be considered during the treatment period.

---

Q: How does the 'Lipocream' formulation affect the skin penetration of the drug?

The Lipocream formulation is a specialized base with an optimized lipid content. This composition is intended to facilitate effective drug delivery and absorption of the active ingredient into the skin compared to standard creams.

---

Q: What is the risk of skin thinning (atrophy) with this specific formulation?

The official safety information lists thinning of the skin (atrophy) as a possible adverse reaction to this topical corticosteroid. However, the exact rate or incidence of this specific side effect with the Lipocream formulation is noted as not known in regulatory documents.

---

Q: Is acne or breakouts a known side effect of Локоид Липокрем?

Official safety information from regulatory documents lists adverse reactions such as acne and pimples (breakouts) under the category of rare skin and subcutaneous tissue disorders.

---

Q: Do older adults need to take special precautions when using Локоид Липокрем?

Regulatory documents do not specify a unique dosage regimen for older adults. Official information indicates that appropriate studies have not demonstrated geriatric-specific problems that would limit the usefulness of this product in this population.

---

Q: What distinguishes Локоид Липокрем's base from a standard cream base?

Локоид Липокрем utilizes a specialized base described as a hydrophilic cream with an optimized lipid content. This unique formulation provides a moisturizing emollient effect while also being designed for improved delivery of the active ingredient into the skin.

---

Q: Is the cream known to cause discoloration or changes in skin pigmentation?

Official safety data lists changes in skin color (pigmentation) as a possible adverse reaction related to skin and subcutaneous tissue disorders. Regulatory documents note that the specific incidence rate for this change is not known.

---

Q: What information is available about potential withdrawal effects after stopping use?

Regulatory reviews acknowledge that Topical Steroid Withdrawal reactions have been reported in medical literature. These reactions, which can include a worsening of skin condition, are typically associated with stopping use after the product has been applied continuously for a prolonged duration.

---

Q: How does the official literature describe the safety profile of Локоид Липокрем?

The safety profile is well-documented in official literature, with the most frequently observed adverse reactions being localized to the application site. However, regulatory warnings exist about the risk of systemic adverse effects—such as HPA axis suppression—if the cream is used over large body surface areas or under occlusive dressings.

---

Q: Can this drug be used by patients with diabetes, according to regulatory sources?

Systemic adverse reactions associated with topical corticosteroids may include manifestations like hyperglycemia (high blood sugar) and glucosuria. Official information suggests that patients with conditions such as diabetes may need to have their status periodically evaluated while using the product.

---

Q: Does the cream contain any common allergens, such as lanolin or parabens?

Regulatory documents listing the inactive ingredients show that the formulation may contain preservatives like propylparaben and butylparaben. Patients who have known sensitivities may wish to review the full list of inactive ingredients prior to use.

---

Q: What is the key functional difference between a cream and a lipocream formulation?

The key functional difference of the Lipocream formulation lies in its composition, which is formulated to optimize the delivery of the active ingredient into the skin. Additionally, the base provides a complementary emollient effect to help moisturize the skin.

---

Q: Can the cream be used on broken skin or open wounds?

The cream is specified strictly for cutaneous (topical) use. Official information warns that conditions like inflammation and altered skin barriers can increase percutaneous absorption, indicating that caution is advised when applying the product to non-intact skin or open wounds.

---

Q: Is it described as having a systemic effect on the body?

No, the product is intended only for local cutaneous use. However, regulatory information warns that systemic absorption can still occur, particularly with prolonged use or over large areas, which carries the risk of systemic adverse effects like suppression of the HPA axis.

---

Q: Is there a risk of rebound flare-ups after discontinuing the use of the product?

Regulatory reviews acknowledge that a severe rebound effect (flare-up of the treated condition) can occur after discontinuing the use of a topical steroid. This phenomenon is typically associated with stopping higher-strength products that have been used continuously for prolonged periods.

---

Q: Do regulatory bodies classify Локоид Липокрем as a short-term or long-term treatment option?

The official drug protocol mandates a short-term duration of use, generally recommending therapy be limited to the least amount of time compatible with an effective regimen. Therapy is typically meant to be discontinued once the symptoms are under control, and duration should generally not exceed four weeks.

---

Q: Can I use the cream if I am also taking oral steroid medication?

Co-administration with other topical or systemic corticosteroids, including oral steroid medication, is documented as potentially resulting in additive systemic glucocorticoid exposure. Official warnings specify that the cumulative systemic effect of all steroid products being used is a critical factor for professional consideration.

---

Q: Is it possible to become dependent on Локоид Липокрем?

The phenomenon of Topical Corticosteroid Dependence has been reported in medical literature related to topical steroid use, which can result in a severe flare-up of the treated skin condition when the product is stopped. This reaction is generally associated with long-term, continuous application.

---

Q: Can applying too much Локоид Липокрем increase the risk of side effects?

Official administration instructions specify that a thin layer should be applied to the affected area. Regulatory guidance warns against using more of the product than directed or for a longer period of time, as this may increase the risk of unwanted side effects or elevated systemic absorption.

---

Q: What happens if Локоид Липокрем is accidentally applied near the eyes?

Official warnings advise strictly avoiding contact with the eyes due to the potential risk of serious ophthalmic reactions, such as cataracts and glaucoma. If accidental contact occurs and visual symptoms develop, consulting a healthcare provider or eye specialist for evaluation is recommended.

---

Q: Is there a maximum surface area of the body recommended for treatment with Локоид Липокрем?

Regulatory documents do not provide a specific maximum percentage of body surface area for treatment. Instead, they warn that use over large surface areas is a condition that increases systemic absorption and requires professional evaluation to monitor for potential adverse effects.

How to Store and Dispose of Locoid Lipocream

Official regulatory labeling dictates specific conditions for storing Locoid Lipocream (Hydrocortisone butyrate 0.1% cream) to maintain product stability.

Storage Requirements

The cream must be stored at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). The product must not be refrigerated or frozen. Protection from heat, moisture, and direct light is required, and the container should be kept closed. As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children.

---

Disposal

Patients should not keep outdated medicine or medicine that is no longer needed. Unused or expired Locoid Lipocream must be properly discarded according to the instructions provided by a pharmacist or healthcare professional.